Acquiring Company
PTC Therapeutics
Acquired Company
Sangamo Therapeutics
South PlainfieldBrisbaneBiotechnologyBiotechnologyHealth CareGeneticsTherapeuticsDescription
PTC Therapeutics has announced its acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million, plus potential milestone payments. This acquisition is expected to enhance PTC's rare disease portfolio and leverage its existing commercial infrastructure. The BLA submission is projected to be completed in Q4 2026, with a potential commercial launch in 2027.
Don't miss PTC Therapeutics's next move
Get an email the moment PTC Therapeutics makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Sangamo Therapeutics?
Sangamo Therapeutics was acquired by PTC Therapeutics, based in South Plainfield. The deal was reported on August 12, 2026. PTC Therapeutics is a biopharmaceutical company that engages in the discovery, development and commercialization of small-molecule drugs. PTC Therapeutics is publicly traded (PTCT) and operates in Biotechnology.
When did PTC Therapeutics acquire Sangamo Therapeutics?
PTC Therapeutics's acquisition of Sangamo Therapeutics was reported on August 12, 2026. PTC Therapeutics has announced its acquisition of ST-920, a BLA-stage gene therapy for Fabry disease, from Sangamo Therapeutics for $111 million, plus potential milestone payments. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Sangamo Therapeutics do?
Sangamo Therapeutics, Inc. is a genomic medicine company based in California. It is publicly traded (SGMOQ), operating in Biotechnology, and is based in Brisbane.